Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Hycamtin

Synonyms: topotecan, Hycamtamine, NSC609699, SKF-104864-A, NSC 609699, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hycamtin

Mucositis was dose limiting and correlated with topotecan dose level and area under the curve (AUC) [1].

Associations of Hycamtin with other chemical compounds

The recommended schedule is 2.0 mg oral topotecan plus 100 mg elacridar administered concomitantly daily times five every 21 days [2].
Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts [3].

References

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Perkins, J.B., Goldstein, S.C., Dawson, J.L., Kim, J., Field, T.L., Partyka, J.S., Fields, K.K., Maddox, B.L., Simonelli, C.E., Neuger, A.M., Lush, R.M., Sullivan, D.M. Clin. Cancer Res. (2011) [Pubmed]
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Kuppens, I.E., Witteveen, E.O., Jewell, R.C., Radema, S.A., Paul, E.M., Mangum, S.G., Beijnen, J.H., Voest, E.E., Schellens, J.H. Clin. Cancer Res. (2007) [Pubmed]
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Molina, J.R., Kaufmann, S.H., Reid, J.M., Rubin, S.D., Gálvez-Peralta, M., Friedman, R., Flatten, K.S., Koch, K.M., Gilmer, T.M., Mullin, R.J., Jewell, R.C., Felten, S.J., Mandrekar, S., Adjei, A.A., Erlichman, C. Clin. Cancer Res. (2008) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share